Details of the Drug

General Information of Drug (ID: DMEN6X7)

Drug Name
Atropine
Synonyms
dl-Hyoscyamine; Atropin; Atropen; dl-Tropyltropate; Atropinol; Atropina; Eyesules; Troyl tropate; Isopto-atropine; Atropin [German]; Atropina [Italian]; Atropin-flexiolen; (+,-)-Tropyl tropate; 51-55-8; DL-Tropyl tropate; Tropine, tropate (ester); Tropic acid, ester with tropine; Atropine sulfate; CCRIS 3080; Atropine (USP); Isopto Atropine; Tropic acid, 3-alpha-tropanyl ester; Atropt; HSDB 2199; DL-Tropanyl; Anaspaz; Atropair; Atrosulf; Belladenal; Cytospaz; Minims; Tropanol; Urised; Atropine Care; Atropine [BAN]; Atropinium cation; Hyoscyamine sulfate; Minims Atropine; OR22908; Atropen (TN); Bellergal-S; D1-hyoscyamine; Dl-Hyoscyamine; Dl-Tropyltropate; I-Tropine; NP-010662; Neo-Diophen; Ocu-Tropine; Protamine & Atropine; Atropinium(1+); Tropan-3alpha-ol; Tropan-3beta-ol; Atropine Sulfate SOP; DL-Tropanyl 2-hydroxy-1-phenylpropionate; Beta-Phenyl-gamma-oxypropionsaeure-tropyl-ester [German]; Beta-Phenyl-gamma-oxypropionsaure-tropyl-ester [German]; Tropan-3alpha-yl 3-hydroxy-2-phenylpropanoate; Endo-8-methyl-8-azabicyclo[321]octan-3-ol; B eta-(Hydroxymethyl)benzeneacetic acid 8-methyl-8-azabicyclo[321]oct-3-yl ester; [(1R,5S)-8-methyl-8-azabicyclo[321]octan-3-yl] 3-hydroxy-2-phenylpropanoate; [(1S,5R)-8-methyl-8-azabicyclo[321]oct-3-yl] 3-hydroxy-2-phenyl-propanoate; Endo-(+/-)-alpha-(Hydroxymethyl)benzeneacetic acid 8-methyl-8-azabicyclo[321]oct-3-yl ester; Benzeneacetic acid, alpha-(hydroxymethyl)-, (3-endo)-8-methyl-8-azabicyclo(321)oct-3-yl ester; (3-endo)-8-methyl-8-azabicyclo[321]oct-3-yl (2S)-3-hydroxy-2-phenylpropanoate; (3-endo)-8-methyl-8-azabicyclo[321]oct-3-yl 3-hydroxy-2-phenylpropanoate; (3-endo)-8-methyl-8-azabicyclo[321]oct-3-yl tropate; (3-endo)-8-methyl-8-azabicyclo[321]octan-3-ol; (3-endo,8-syn)-3-[(3-hydroxy-2-phenylpropanoyl)oxy]-8-methyl-8-azoniabicyclo[321]octane; (3-exo)-8-methyl-8-azabicyclo[321]octan-3-ol; 1-alpha-H,5-alpha-H-Tropan-3-alpha-ol (+-)-tropate (ester); 1-alpha-H,5-alpha-H-Tropan-3-alpha-ol (+-)-tropate (ester) (8CI); 1alphaH,5alphaH-Tropan-3alpha-ol; 1alphaH,5alphaH-Tropan-3alpha-ol (+-)-tropate (ester); 1alphaH,5alphaH-Tropan-3beta-ol; 2-Phenylhydracrylic acid 3-alpha-tropanyl ester; 8-Methyl-8-azabicyclo[321]oct-3-yl 3-hydroxy-2-phenylpropanoate; 8-Methyl-8-azabicyclo[321]oct-3-yl tropate; 8-Methyl-8-azabicyclo[321]octan-3-yl 3-hydroxy-2-phenylpropionate
Indication
Disease Entry ICD 11 Status REF
Organophosphate poisoning NE6Z Approved [1], [2]
Poison intoxication NE6Z Phase 1 [1], [3], [4]
Therapeutic Class
Antiarrhythmic Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 289.4
Topological Polar Surface Area (xlogp) 1.8
Rotatable Bond Count (rotbonds) 5
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 4
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability [5]
Clearance
The drug present in the plasma can be removed from the body at the rate of 7.6 mL/min/kg [6]
Elimination
57% of drug is excreted from urine in the unchanged form [5]
Half-life
The concentration or amount of drug in body reduced by one-half in 3.0 +/-0.9 hours [6]
Metabolism
The drug is metabolized via the enzymatic hydrolysis in the liver [7]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.03 micromolar/kg/day [8]
Unbound Fraction
The unbound fraction of drug in plasma is 0.61% [6]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 3.3 L/kg [6]
Water Solubility
The ability of drug to dissolve in water is measured as 0.002 mg/mL [5]
Chemical Identifiers
Formula
C17H23NO3
IUPAC Name
[(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate
Canonical SMILES
CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3
InChI
InChI=1S/C17H23NO3/c1-18-13-7-8-14(18)10-15(9-13)21-17(20)16(11-19)12-5-3-2-4-6-12/h2-6,13-16,19H,7-11H2,1H3/t13-,14+,15?,16?
InChIKey
RKUNBYITZUJHSG-PJPHBNEVSA-N
Cross-matching ID
PubChem CID
174174
ChEBI ID
CHEBI:16684
CAS Number
51-55-8
DrugBank ID
DB00572
TTD ID
D0RG3O
VARIDT ID
DR00665
ACDINA ID
D00851

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Muscarinic acetylcholine receptor M5 (CHRM5) TTH18TF ACM5_HUMAN Antagonist [9], [10], [11], [12]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Organic cation transporter 1 (SLC22A1) DTT79CX S22A1_HUMAN Substrate [13]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Atropine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Bethanechol DMCLHO0 Moderate Antagonize the effect of Atropine when combined with Bethanechol. Abnormal micturition [MF50] [34]
Sodium bicarbonate DMMU6BJ Moderate Decreased absorption of Atropine due to adsorption of Sodium bicarbonate. Acidosis [5C73] [35]
Oliceridine DM6MDCF Moderate Additive antimotility effects by the combination of Atropine and Oliceridine. Acute pain [MG31] [36]
Scopolamine DMOM8AL Moderate Additive anticholinergic effects by the combination of Atropine and Scopolamine. Addictive disorder [6C50-6C5Z] [37]
Mepyramine DMB4SFH Moderate Additive anticholinergic effects by the combination of Atropine and Mepyramine. Allergic/hypersensitivity disorder [4A80-4A8Z] [38]
Phenyltoloxamine DMKAEQW Moderate Additive anticholinergic effects by the combination of Atropine and Phenyltoloxamine. Allergic/hypersensitivity disorder [4A80-4A8Z] [38]
Tripelennamine DMZBU15 Moderate Additive anticholinergic effects by the combination of Atropine and Tripelennamine. Allergic/hypersensitivity disorder [4A80-4A8Z] [37]
Memantine DMD9WSC Moderate Additive anticholinergic effects by the combination of Atropine and Memantine. Alzheimer disease [8A20] [37]
Galantamine DMEO794 Moderate Antagonize the effect of Atropine when combined with Galantamine. Alzheimer disease [8A20] [39]
Rivastigmine DMG629M Moderate Antagonize the effect of Atropine when combined with Rivastigmine. Alzheimer disease [8A20] [39]
Donepezil DMIYG7Z Moderate Antagonize the effect of Atropine when combined with Donepezil. Alzheimer disease [8A20] [40]
Desipramine DMT2FDC Moderate Additive anticholinergic effects by the combination of Atropine and Desipramine. Attention deficit hyperactivity disorder [6A05] [37]
Cariprazine DMJYDVK Moderate Additive anticholinergic effects by the combination of Atropine and Cariprazine. Bipolar disorder [6A60] [37]
Loperamide DMOJZQ9 Moderate Additive antimotility effects by the combination of Atropine and Loperamide. Bowel habit change [ME05] [41]
Acetylcholine DMDF79Z Moderate Antagonize the effect of Atropine when combined with Acetylcholine. Cataract [9B10] [42]
Umeclidinium DM4E8O9 Moderate Additive anticholinergic effects by the combination of Atropine and Umeclidinium. Chronic obstructive pulmonary disease [CA22] [43]
Tiotropium DMFDC0Q Moderate Additive anticholinergic effects by the combination of Atropine and Tiotropium. Chronic obstructive pulmonary disease [CA22] [43]
Dihydrocodeine DMB0FWL Moderate Additive CNS depression effects by the combination of Atropine and Dihydrocodeine. Chronic pain [MG30] [44]
Olopatadine DMKMWQG Moderate Additive CNS depression effects by the combination of Atropine and Olopatadine. Conjunctiva disorder [9A60] [45]
Alfentanil DMVO0UB Moderate Additive antimotility effects by the combination of Atropine and Alfentanil. Corneal disease [9A76-9A78] [36]
Arbutamine DMCY8AF Moderate Increased risk of rapid heart rate by the combination of Atropine and Arbutamine. Coronary atherosclerosis [BA80] [46]
Ethanol DMDRQZU Moderate Additive CNS depression effects by the combination of Atropine and Ethanol. Cystitis [GC00] [47]
Cyclobenzaprine DM1YBRM Moderate Additive anticholinergic effects by the combination of Atropine and Cyclobenzaprine. Depression [6A70-6A7Z] [37]
Isocarboxazid DMAF1NB Minor Additive anticholinergic effects by the combination of Atropine and Isocarboxazid. Depression [6A70-6A7Z] [37]
Tranylcypromine DMGB5RE Minor Additive anticholinergic effects by the combination of Atropine and Tranylcypromine. Depression [6A70-6A7Z] [37]
OPC-34712 DMHG57U Moderate Additive anticholinergic effects by the combination of Atropine and OPC-34712. Depression [6A70-6A7Z] [37]
Phenelzine DMHIDUE Minor Additive anticholinergic effects by the combination of Atropine and Phenelzine. Depression [6A70-6A7Z] [37]
Clomipramine DMINRKW Moderate Additive anticholinergic effects by the combination of Atropine and Clomipramine. Depression [6A70-6A7Z] [37]
Doxepin DMPI98T Moderate Additive anticholinergic effects by the combination of Atropine and Doxepin. Depression [6A70-6A7Z] [38]
Maprotiline DMPWB7T Moderate Additive anticholinergic effects by the combination of Atropine and Maprotiline. Depression [6A70-6A7Z] [37]
Nitroglycerin DMQ2491 Minor Decreased dissolution of Atropine taken sublingually caused by Nitroglycerin. Diabetic foot ulcer [BD54] [48]
Mepenzolate DM8YU2F Moderate Additive anticholinergic effects by the combination of Atropine and Mepenzolate. Digestive system disease [DE2Z] [37]
Oxybutynine DMJPBAX Moderate Additive anticholinergic effects by the combination of Atropine and Oxybutynine. Discovery agent [N.A.] [37]
Meclizine DMS7T13 Moderate Additive anticholinergic effects by the combination of Atropine and Meclizine. Dizziness and giddiness [MB48] [37]
Zonisamide DM0DTF7 Major Additive CNS depression effects by the combination of Atropine and Zonisamide. Epilepsy/seizure [8A61-8A6Z] [49]
Diphenhydramine DMKQTBA Moderate Additive anticholinergic effects by the combination of Atropine and Diphenhydramine. Episodic vestibular syndrome [AB31] [37]
Nadolol DMW6GVL Moderate Antagonize the effect of Atropine when combined with Nadolol. Essential hypertension [BA00] [35]
Solifenacin DMG592Q Moderate Additive anticholinergic effects by the combination of Atropine and Solifenacin. Functional bladder disorder [GC50] [37]
Tolterodine DMSHPW8 Moderate Additive anticholinergic effects by the combination of Atropine and Tolterodine. Functional bladder disorder [GC50] [37]
Ketoconazole DMPZI3Q Moderate Decreased absorption of Atropine due to altered gastric pH caused by Ketoconazole. Fungal infection [1F29-1F2F] [50]
Propantheline DM2EN6G Moderate Additive anticholinergic effects by the combination of Atropine and Propantheline. Gastric ulcer [DA60] [37]
Cisapride DMY7PED Moderate Antagonize the effect of Atropine when combined with Cisapride. Gastro-oesophageal reflux disease [DA22] [51]
Isoflurophate DMBSK7X Moderate Antagonize the effect of Atropine when combined with Isoflurophate. Glaucoma [9C61] [42]
Pilocarpine DMV9ADG Moderate Antagonize the effect of Atropine when combined with Pilocarpine. Glaucoma [9C61] [34]
Carvedilol DMHTEAO Moderate Antagonize the effect of Atropine when combined with Carvedilol. Heart failure [BD10-BD1Z] [35]
Chlorothiazide DMLHESP Minor Altered absorption of Atropine due to GI dynamics variation caused by Chlorothiazide. Heart failure [BD10-BD1Z] [52]
Hydroflumethiazide DMVPUQI Minor Altered absorption of Atropine due to GI dynamics variation caused by Hydroflumethiazide. Heart failure [BD10-BD1Z] [52]
Acebutolol DM0TI4U Moderate Antagonize the effect of Atropine when combined with Acebutolol. Hypertension [BA00-BA04] [35]
Bisoprolol DM3UZ95 Moderate Antagonize the effect of Atropine when combined with Bisoprolol. Hypertension [BA00-BA04] [35]
Penbutolol DM4ES8F Moderate Antagonize the effect of Atropine when combined with Penbutolol. Hypertension [BA00-BA04] [35]
Nebivolol DM7F1PA Moderate Antagonize the effect of Atropine when combined with Nebivolol. Hypertension [BA00-BA04] [35]
Pindolol DMD2NV7 Moderate Antagonize the effect of Atropine when combined with Pindolol. Hypertension [BA00-BA04] [35]
Indapamide DMGN1PW Minor Altered absorption of Atropine due to GI dynamics variation caused by Indapamide. Hypertension [BA00-BA04] [52]
Trichlormethiazide DMHAQCO Minor Altered absorption of Atropine due to GI dynamics variation caused by Trichlormethiazide. Hypertension [BA00-BA04] [52]
Labetalol DMK8U72 Moderate Antagonize the effect of Atropine when combined with Labetalol. Hypertension [BA00-BA04] [35]
Hydrochlorothiazide DMUSZHD Minor Altered absorption of Atropine due to GI dynamics variation caused by Hydrochlorothiazide. Hypertension [BA00-BA04] [52]
Potassium chloride DMMTAJC Major Altered absorption of Atropine due to GI dynamics variation caused by Potassium chloride. Hypo-kalaemia [5C77] [53]
Belladonna DM2RBWK Moderate Additive anticholinergic effects by the combination of Atropine and Belladonna. Infectious gastroenteritis/colitis [1A40] [37]
Amantadine DMS3YE9 Moderate Additive anticholinergic effects by the combination of Atropine and Amantadine. Influenza [1E30-1E32] [54]
Propiomazine DMKY8V1 Moderate Additive anticholinergic effects by the combination of Atropine and Propiomazine. Insomnia [7A00-7A0Z] [37]
ITI-007 DMUQ1DO Moderate Additive anticholinergic effects by the combination of Atropine and ITI-007. Insomnia [7A00-7A0Z] [37]
R0-93877 DMM4U9G Moderate Antagonize the effect of Atropine when combined with R0-93877. Irritable bowel syndrome [DD91] [55]
Clidinium DMUMQZ0 Moderate Additive anticholinergic effects by the combination of Atropine and Clidinium. Irritable bowel syndrome [DD91] [37]
Dicyclomine DMZSDGX Moderate Additive anticholinergic effects by the combination of Atropine and Dicyclomine. Irritable bowel syndrome [DD91] [37]
Physostigmine DM2N0TO Moderate Antagonize the effect of Atropine when combined with Physostigmine. Lips/oral mucosa miscellaneous disorder [DA02] [39]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Atropine and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [56]
Lasmiditan DMXLVDT Moderate Additive CNS depression effects by the combination of Atropine and Lasmiditan. Migraine [8A80] [57]
Flibanserin DM70DTN Moderate Additive CNS depression effects by the combination of Atropine and Flibanserin. Mood disorder [6A60-6E23] [58]
Neostigmine DM6T2J3 Moderate Antagonize the effect of Atropine when combined with Neostigmine. Myasthenia gravis [8C6Y] [59]
Edrophonium DMCRQHB Moderate Antagonize the effect of Atropine when combined with Edrophonium. Myasthenia gravis [8C6Y] [59]
Ambenonium DMOP0BL Moderate Antagonize the effect of Atropine when combined with Ambenonium. Myasthenia gravis [8C6Y] [59]
Phenindamine DMDTC7R Moderate Additive anticholinergic effects by the combination of Atropine and Phenindamine. Nasopharyngitis [CA00] [37]
Dimenhydrinate DM264B3 Moderate Additive anticholinergic effects by the combination of Atropine and Dimenhydrinate. Nausea/vomiting [MD90] [37]
Promethazine DM6I5GR Moderate Additive anticholinergic effects by the combination of Atropine and Promethazine. Nausea/vomiting [MD90] [37]
Cyclizine DM9G7BS Moderate Additive anticholinergic effects by the combination of Atropine and Cyclizine. Nausea/vomiting [MD90] [37]
Metoclopramide DMFA5MY Moderate Antagonize the effect of Atropine when combined with Metoclopramide. Nausea/vomiting [MD90] [60]
Polythiazide DMCH80F Minor Altered absorption of Atropine due to GI dynamics variation caused by Polythiazide. Oedema [MG29] [52]
Pentazocine DM1XBHS Moderate Additive antimotility effects by the combination of Atropine and Pentazocine. Pain [MG30-MG3Z] [36]
Dextropropoxyphene DM23HCX Moderate Additive CNS depression effects by the combination of Atropine and Dextropropoxyphene. Pain [MG30-MG3Z] [44]
Butorphanol DM5KYPJ Moderate Additive antimotility effects by the combination of Atropine and Butorphanol. Pain [MG30-MG3Z] [36]
Oxymorphone DM65AGJ Moderate Additive antimotility effects by the combination of Atropine and Oxymorphone. Pain [MG30-MG3Z] [36]
Levorphanol DMGS80V Moderate Additive antimotility effects by the combination of Atropine and Levorphanol. Pain [MG30-MG3Z] [36]
Dezocine DMJDB0Y Moderate Additive antimotility effects by the combination of Atropine and Dezocine. Pain [MG30-MG3Z] [36]
Flavoxate DMKV4NL Moderate Additive anticholinergic effects by the combination of Atropine and Flavoxate. Pain [MG30-MG3Z] [37]
Nalbuphine DMOSQGU Moderate Additive antimotility effects by the combination of Atropine and Nalbuphine. Pain [MG30-MG3Z] [36]
Buprenorphine DMPRI8G Moderate Additive antimotility effects by the combination of Atropine and Buprenorphine. Pain [MG30-MG3Z] [36]
Hydrocodone DMQ2JO5 Moderate Additive antimotility effects by the combination of Atropine and Hydrocodone. Pain [MG30-MG3Z] [36]
Biperiden DME78OA Moderate Additive anticholinergic effects by the combination of Atropine and Biperiden. Parkinsonism [8A00] [37]
Levodopa DMN3E57 Moderate Altered absorption of Atropine due to GI dynamics variation caused by Levodopa. Parkinsonism [8A00] [61]
Orphenadrine DMW542E Moderate Additive anticholinergic effects by the combination of Atropine and Orphenadrine. Parkinsonism [8A00] [37]
Methylscopolamine DM5VWOB Moderate Additive anticholinergic effects by the combination of Atropine and Methylscopolamine. Peptic ulcer [DA61] [37]
Levomepromazine DMIKFEL Moderate Additive anticholinergic effects by the combination of Atropine and Levomepromazine. Psychotic disorder [6A20-6A25] [37]
Fluphenazine DMIT8LX Moderate Additive anticholinergic effects by the combination of Atropine and Fluphenazine. Psychotic disorder [6A20-6A25] [37]
Quetiapine DM1N62C Moderate Additive anticholinergic effects by the combination of Atropine and Quetiapine. Schizophrenia [6A20] [37]
Mesoridazine DM2ZGAN Moderate Additive anticholinergic effects by the combination of Atropine and Mesoridazine. Schizophrenia [6A20] [37]
Thioridazine DM35M8J Moderate Additive anticholinergic effects by the combination of Atropine and Thioridazine. Schizophrenia [6A20] [37]
Aripiprazole DM3NUMH Moderate Additive anticholinergic effects by the combination of Atropine and Aripiprazole. Schizophrenia [6A20] [37]
Iloperidone DM6AUFY Moderate Additive anticholinergic effects by the combination of Atropine and Iloperidone. Schizophrenia [6A20] [37]
Paliperidone DM7NPJS Moderate Additive anticholinergic effects by the combination of Atropine and Paliperidone. Schizophrenia [6A20] [37]
Perphenazine DMA4MRX Moderate Additive anticholinergic effects by the combination of Atropine and Perphenazine. Schizophrenia [6A20] [37]
Molindone DMAH70G Moderate Additive anticholinergic effects by the combination of Atropine and Molindone. Schizophrenia [6A20] [37]
Thiothixene DMDINC4 Moderate Additive anticholinergic effects by the combination of Atropine and Thiothixene. Schizophrenia [6A20] [37]
Trifluoperazine DMKBYWI Moderate Additive anticholinergic effects by the combination of Atropine and Trifluoperazine. Schizophrenia [6A20] [37]
Risperidone DMN6DXL Moderate Additive anticholinergic effects by the combination of Atropine and Risperidone. Schizophrenia [6A20] [37]
Asenapine DMSQZE2 Moderate Additive anticholinergic effects by the combination of Atropine and Asenapine. Schizophrenia [6A20] [37]
Pimozide DMW83TP Moderate Additive anticholinergic effects by the combination of Atropine and Pimozide. Schizophrenia [6A20] [37]
Fentanyl DM8WAHT Moderate Additive antimotility effects by the combination of Atropine and Fentanyl. Sensation disturbance [MB40] [36]
Sufentanil DMU7YEL Moderate Additive antimotility effects by the combination of Atropine and Sufentanil. Sensation disturbance [MB40] [36]
Tizanidine DMR2IQ4 Moderate Additive CNS depression effects by the combination of Atropine and Tizanidine. Tonus and reflex abnormality [MB47] [62]
Pramlintide DM0EZ9Q Moderate Altered absorption of Atropine due to GI dynamics variation caused by Pramlintide. Type-1/2 diabete [5A10-5A11] [63]
Nitrofurantoin DM7PQIK Minor Altered absorption of Atropine due to GI dynamics variation caused by Nitrofurantoin. Urinary tract infection [GC08] [64]
Chlorpheniramine DM5URA2 Moderate Additive anticholinergic effects by the combination of Atropine and Chlorpheniramine. Vasomotor/allergic rhinitis [CA08] [37]
Methdilazine DMAUHQX Moderate Additive anticholinergic effects by the combination of Atropine and Methdilazine. Vasomotor/allergic rhinitis [CA08] [37]
Carbinoxamine DMCT31R Moderate Additive anticholinergic effects by the combination of Atropine and Carbinoxamine. Vasomotor/allergic rhinitis [CA08] [37]
Trimeprazine DMEMV9D Moderate Additive anticholinergic effects by the combination of Atropine and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [38]
Acrivastine DMTIGA0 Moderate Additive anticholinergic effects by the combination of Atropine and Acrivastine. Vasomotor/allergic rhinitis [CA08] [37]
Azatadine DMZ80SB Moderate Additive anticholinergic effects by the combination of Atropine and Azatadine. Vasomotor/allergic rhinitis [CA08] [37]
⏷ Show the Full List of 117 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Sodium citrate anhydrous E00102 6224 Alkalizing agent; Buffering agent; Complexing agent; Emulsifying agent
Sulfuric acid E00045 1118 Acidulant
Citric acid monohydrate E00271 22230 Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
Nitrogen E00033 947 Aerosol propellant; Sparging agent
Sodium chloride E00077 5234 Diluent; Tonicity agent
Sodium hydroxide E00234 14798 Alkalizing agent
Water E00035 962 Solvent
Lanolin E00375 75778 Emollient; Emulsifying agent; Ointment base
⏷ Show the Full List of 8 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Atropine 0.25mg/0.3ml solution 0.25mg/0.3ml Solution Intravenous
Atropine 0.5mg/0.7ml solution 0.5mg/0.7ml Solution Intravenous
Atropine 1mg/0.7ml solution 1mg/0.7ml Solution Intravenous
Atropine 2mg/0.7ml solution 2mg/0.7ml Solution Intravenous
Atropine 1mg/10ml solution 1mg/10ml Solution Intravenous
Atropine 1% ointment 1% Ointment Ophthalmic
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 320).
2 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 071295.
3 Potentiation and inhibition of neuronal nicotinic receptors by atropine: competitive and noncompetitive effects. Mol Pharmacol. 1997 Nov;52(5):886-95.
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
5 BDDCS applied to over 900 drugs
6 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
7 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
8 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
9 Additive protective effects of donepezil and nicotine against salsolinol-induced cytotoxicity in SH-SY5Y cells. Neurotox Res. 2009 Oct;16(3):194-204.
10 Loss of M2 muscarinic receptor function inhibits development of hypoxic bradycardia and alters cardiac beta-adrenergic sensitivity in larval zebraf... Am J Physiol Regul Integr Comp Physiol. 2009 Aug;297(2):R412-20.
11 The effects of the antagonists of muscarinic acetylcholine receptor subtypes in rat brain on urinary bladder contraction. Nippon Hinyokika Gakkai Zasshi. 2002 Mar;93(3):427-34.
12 The muscarinic antagonists aprophen and benactyzine are noncompetitive inhibitors of the nicotinic acetylcholine receptor. Mol Pharmacol. 1987 Nov;32(5):678-85.
13 Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42.
14 Are organic cation transporters capable of transporting prostaglandins? Naunyn Schmiedebergs Arch Pharmacol. 2005 Aug;372(2):125-30.
15 Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther. 2006 Nov;319(2):879-86.
16 Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia. Leuk Lymphoma. 2008 Apr;49(4):639-42.
17 Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res. 2006 Sep 1;66(17):8847-57.
18 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
19 Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett. 2006 Mar 8;234(1):4-33.
20 Upregulation of histone acetylation reverses organic anion transporter 2 repression and enhances 5-fluorouracil sensitivity in hepatocellular carcinoma
21 Comparison of type I and type II organic cation transport by organic cation transporters and organic anion-transporting polypeptides. J Pharmacol Exp Ther. 2001 Jul;298(1):110-5.
22 Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences. Drug Metab Pharmacokinet. 2008;23(4):243-53.
23 Influx Transport of Cationic Drug at the Blood-Retinal Barrier: Impact on the Retinal Delivery of Neuroprotectants. Biol Pharm Bull. 2017;40(8):1139-1145.
24 Muscarinic cholinergic and histamine H1 receptor binding of phenothiazine drug metabolites. Life Sci. 1988;43(5):405-12.
25 Design, synthesis, and neurochemical evaluation of 5-(3-alkyl-1,2,4- oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidines as M1 muscarinic receptor agonists. J Med Chem. 1993 Apr 2;36(7):842-7.
26 Retinoic acid prevents virus-induced airway hyperreactivity and M2 receptor dysfunction via anti-inflammatory and antiviral effects. Am J Physiol Lung Cell Mol Physiol. 2009 Aug;297(2):L340-6.
27 Medicinal plants in therapy. Bull World Health Organ. 1985;63(6):965-81.
28 Affinity profiles of various muscarinic antagonists for cloned human muscarinic acetylcholine receptor (mAChR) subtypes and mAChRs in rat heart and submandibular gland. Life Sci. 1999;64(25):2351-8.
29 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7354).
30 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
31 Comparison of pharmacological effects of L- and DL-n-butyl-scopolamine in rat uterus. Yao Xue Xue Bao. 1994;29(1):24-7.
32 Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
33 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 467).
34 Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979): 199-255. [PMID: 376469]
35 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
36 Product Information. Apadaz (acetaminophen-benzhydrocodone). KemPharm, Inc, Coralville, IA.
37 Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
38 Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
39 Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC "Explicit criteria for determining inappropriate medication use in nursing home residents." Arch Intern Med 151 (1991): 1825-32. [PMID: 1888249]
40 Katz IR, Sands LP, Bilker W, DiFilippo S, Boyce A, D'Angelo K "Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride." J Am Geriatr Soc 46 (1998): 8-13. [PMID: 9434659]
41 Eronen M, Putkonen H, Hallikainen T, Vartiainen H "Lethal gastroenteritis associated with clozapine and loperamide." Am J Psychiatry 160 (2003): 2242-2243. [PMID: 14638602]
42 Multum Information Services, Inc. Expert Review Panel.
43 Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21. [PMID: 23170031]
44 Product Information. Exalgo (hydromorphone). Covidien, Mansfield, MA.
45 Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
46 Product Information. GenESA (arbutamine). Gensia Inc, San Diego, CA.
47 Linnoila M "Drug effects on psychomotor skills related to driving: interaction of atropine, glycopyrrhonium and alcohol." Eur J Clin Pharmacol 6 (1973): 107-12. [PMID: 4588850]
48 Product Information. Nitrostat (nitroglycerin). Parke-Davis, Morris Plains, NJ.
49 Product Information. Zonegran (zonisamide) Elan Pharmaceuticals, S. San Francisco, CA.
50 Product Information. Nizoral (ketoconazole). Janssen Pharmaceutica, Titusville, NJ.
51 Product Information. Propulsid (cisapride). Janssen Pharmaceutica, Titusville, NJ.
52 Beermann B, Groschinsky-Grind M "Enhancement of the gastrointestinal absorption of hydrochlorothiazide by propantheline." Eur J Clin Pharmacol 13 (1978): 385-7. [PMID: 668798]
53 Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975): 206. [PMID: 1148734]
54 Postma JU, van Tilburg W "Visual hallucinations and delirium during treatment with amantadine (Symmetrel)." J Am Geriatr Soc 23 (1975): 212-5. [PMID: 123540]
55 EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
56 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
57 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
58 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
59 Product Information. Mestinon (pyridostigmine). ICN Pharmaceuticals Inc, Cost Mesa, CA.
60 Product Information. Motilium (domperidone). Janssen-Ortho Inc, Toronto, ON.
61 Algeri S, Cerletti C, Curcio M, et al. "Effect of anticholinergic drugs on gastro-intestinal absorption of L-dopa in rats and man." Eur J Pharmacol 35 (1976): 293-9. [PMID: 1248506]
62 Product Information. Zanaflex (tizanidine). Acorda Therapeutics, Hawthorne, NY.
63 Product Information. Symlin (pramlintide). Amphastar Pharmaceuticals Inc, South El Monte, CA.
64 Jaffe JM "Effect of propantheline on nitrofurantoin absorption." J Pharm Sci 64 (1975): 1729-30. [PMID: 1185550]